# Kardigan, Inc. Common Stock (KARD)

> Kardigan, Inc. Common Stock (KARD) trades at $12.50 (-5.23%) as of 7:30:02 PM EST on Nov 18, 2026, -8.81% over the past month. Market cap is $1.15B, with 11.2 days to cover in short interest.

Canonical: https://massive.com/quote/kard
Data as of: 2026-11-19T00:30:02.755Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$12.50** -0.69 (-5.23%)
As of 7:30:02 PM EST on Nov 18, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Kardigan, Inc. Common Stock (KARD) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -6.60% |
| 1W | -21.43% |
| 1M | -8.81% |
| YTD | -44.00% |
| 1Y | -44.00% |
| 52-wk range | $12.23 – $27.00 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for KARD: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $12.25 – $13.51 |
| Open | $13.19 |
| Prev close | $13.19 |
| Volume | 546.43K |
| Market cap | $1.15B |
| Shares out | 93.6M |

## Insider trading

[Kardigan, Inc. Common Stock (KARD) insider trading](https://massive.com/quote/kard/insider-trading.md): open-market Form 4 buys and sells by Kardigan, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Kardigan, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Kardigan, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026.”
- Sep 30, 2026 · Director departure
  “On September 29, 2026, Doug Giordano resigned from the board of directors (the "Board") of Kardigan, Inc. (the "Company") and his position on the Audit Committee of the Board (the "Audit Committee"). Mr. Giordano advised the Company that his decision to resign was not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies or practices.”
- Jun 23, 2026 · Charter amendment
  “The Company filed its third amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on June 22, 2026... to, among other things: (i) authorize 700,000,000 shares of common stock; including 500,000,000 shares of voting common stock and 200,000,000 shares of non-voting common stock; (ii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iii) eliminate all references to the previously-existing series of preferred stock; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.”

## KARD short interest

How heavily KARD is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 11.2 |
| Short interest | 5.69M |
| Avg volume | 508.92K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## KARD news

The latest news and headlines about Kardigan, Inc. Common Stock (KARD).

- [Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry \| DelveInsight](https://www.globenewswire.com/news-release/2026/09/16/3363442/0/en/hypertension-clinical-trial-pipeline-accelerates-as-100-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight.html) · GlobeNewswire Inc. · Sep 16, 2026 · positive sentiment

## About Kardigan, Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO | $16.00 on Jun 18, 2026 |

[Kardigan IPO page](https://massive.com/quote/kard/ipo.md)

[Company website](https://www.kardigan.bio)

## FAQ

### What is the Kardigan, Inc. Common Stock (KARD) stock price today?

Kardigan, Inc. Common Stock (KARD) is trading at $12.50 (-5.23% on the day) as of 7:30:02 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Kardigan, Inc. Common Stock?

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist.

### What is the short interest in KARD?

As of Oct 30, 2026, KARD has 5.69M shares short and 11.2 days to cover.

### What exchange is KARD listed on?

Kardigan, Inc. Common Stock (KARD) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time KARD quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=KARD`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Kardigan, Inc. Common Stock (KARD) insider trading](https://massive.com/quote/kard/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
